VB4-P5 Renal Compound Transaction Settled
Filed with ASX · · 2 pages · English
Vectus Biosystems Limited on 6ix
Story so far
Earlier from Vectus Biosystems
- Half Year Report & Appendix 4D
- Quarterly Activities & Appendix 4C Cash Flow Reports
- Response to ASX Query Letter
- Reinstatement to Quotation
- VB4-P5 Renal Compound Transaction
Later from Vectus Biosystems
- Appointment of Dr Tara Speranza as CEO & CTO
- Placement of Shares
- FDA Pre-IND Meeting Request Granted for VB0004
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems